- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.05. | Surrozen secures patent for tissue repair technology | 1 | Investing.com | ||
| SURROZEN Aktie jetzt für 0€ handeln | |||||
| 14.05. | Surrozen, Inc.: Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway | 119 | GlobeNewswire (Europe) | Newly granted patent is part of the expanding intellectual property portfolio directed to: -generating novel and selective Wnt surrogate molecules with potentially broad therapeutic utility and -incorporating... ► Artikel lesen | |
| 09.05. | Surrozen GAAP EPS of -$7.43 misses by $5.65, revenue of $0.98M | 1 | Seeking Alpha | ||
| 09.05. | Surrozen, Inc./DE - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.05. | Surrozen, Inc.: Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update | 786 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively... ► Artikel lesen | |
| 09.05. | Surrozen, Inc./DE - 8-K, Current Report | 1 | SEC Filings | ||
| 31.03. | Surrozen, Inc./DE - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 31.03. | Surrozen, Inc.: Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates | 37 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the... ► Artikel lesen | |
| 31.03. | Surrozen, Inc./DE - 10-K, Annual Report | 1 | SEC Filings | ||
| 31.03. | Surrozen, Inc./DE - 8-K, Current Report | 1 | SEC Filings | ||
| 24.03. | Surrozen, Inc./DE - 8-K, Current Report | 2 | SEC Filings | ||
| 24.03. | Surrozen shifts focus to eye disease treatments, secures $175M funding | 1 | Investing.com | ||
| 24.03. | Surrozen, Inc.: Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases | 1 | GlobeNewswire (USA) | ||
| 24.03. | Surrozen drops sole clinical-stage drug over weak hepatitis data, pivots to eye disease | - | FierceBiotech | ||
| 06.11.24 | Surrozen, Inc.: Surrozen Provides Third Quarter 2024 Financial Results and Business Update | 373 | GlobeNewswire (Europe) | Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected in the first half of 2025 Nominated novel portfolio... ► Artikel lesen | |
| 12.08.24 | Surrozen, Inc.: Surrozen Provides Second Quarter 2024 Financial Results and Business Update | 965 | GlobeNewswire (Europe) | Enrollment ongoing in SZN-043 Phase 1b trial in patients with Severe Alcoholic Hepatitis Presented first-in-human data from SZN-043 Phase 1a trial at EASL Published study that demonstrated application... ► Artikel lesen | |
| 10.06.24 | Surrozen, Inc.: Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan | 581 | GlobeNewswire (Europe) | SZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in preclinical models Treatment with SZN-043 in the Phase 1a trial was safe and well tolerated... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 98,95 | +1,49 % | BioNTech: Milliardendeal mit Bristol Myers Squibb - Aktie schießt ins Plus | BioNTechs Aktien schießen in der US-Vorbörse am Montag regelrecht nach oben: Aktuell werden 106,10 Dollar notiert nach einem NASDAQ-Schlusskurs bei 95,81 Dollar vom Freitag. Der Grund für den Kursanstieg... ► Artikel lesen | |
| EVOTEC | 7,166 | +0,31 % | Evotec, GFT Technologies, InflaRx, Nordex, Rheinmetall, ThyssenKrupp - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| CUREVAC | 3,958 | +1,44 % | CureVac mit SPEZIAL-MELDUNG: Insider kaufen massenhaft Anteile - Das dürfen Sie nicht verpassen! | ||
| AMGEN | 252,35 | +0,34 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,522 | +5,03 % | Defence Therapeutics Inc.: Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub | Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,479 | +5,97 % | NurExone stärkt US-Präsenz und bereitet klinische Studien vor | ||
| IBIO | 0,990 | 0,00 % | iBio, Inc.: iBio Reports Fiscal Third Quarter 2025 Financial Results | SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress.... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 14,860 | +1,33 % | Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses' | ||
| COHERUS ONCOLOGY | 0,693 | -0,46 % | Coherus Oncology, Inc.: Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc.... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 2,978 | +2,48 % | Voyager Therapeutics, Inc.: Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication | LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced... ► Artikel lesen | |
| OPGEN | 2,600 | 0,00 % | OPGEN INC - 8-K, Current Report | ||
| MEREO BIOPHARMA | 2,310 | +3,12 % | Mereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights | Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE... ► Artikel lesen | |
| APELLIS PHARMACEUTICALS | 16,782 | +3,44 % | Apellis Pharmaceuticals, Inc. - 8-K, Current Report | ||
| BENITEC BIOPHARMA | 15,610 | 0,00 % | Benitec Biopharma Inc.: Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update | -Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular... ► Artikel lesen | |
| CYBIN | 7,450 | -1,32 % | CYBIN INC. - 6-K, Report of foreign issuer |
SURROZEN INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 8,550 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SURROZEN INC finden Sie auf Wallstreet Online.